ILMN
ILLUMINA, INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$227.08
−4.67%Year over year
Reported trailing growth
- Revenue
- +5.9%
- EBITDA
- +9.1%
- EBIT
- +21.1%
- EPS
- +31.5%
- Free cash flow
- +5.0%
- Operating cash flow
- +9.6%
Forward estimates
Based on analyst estimates
- Revenue
- +6.8%
- EBITDA
- -6.6%
- EPS
- +1.2%
Three-year CAGR
- Revenue
- -1.8%
- EBITDA
- +301.0%
- EBIT
- +203.7%
- Net income
- +169.5%
- EPS
- +171.3%
- Free cash flow
- +106.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026